Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.74)
# 1,965
Out of 4,944 analysts
47
Total ratings
32.43%
Success rate
45.93%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $9.52 | +57.56% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $2.43 | +681.89% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $11.34 | +164.55% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.05 | +1,995.24% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $4.57 | +425.16% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $21.01 | +494.95% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $2.87 | +527.18% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $2.23 | +752.02% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $2.36 | - | 1 | Oct 1, 2021 | |
| PRTG Portage Biotech | Initiates: Outperform | $600 | $8.71 | +6,788.63% | 1 | Sep 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $79 | $175.40 | -54.86% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $41.74 | +271.35% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $7.56 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $6.20 | +303.23% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61,200 | $9.28 | +659,382.76% | 1 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $2.85 | +63,057.89% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $36.54 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.91 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.91 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $4.61 | +32,437.96% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $3.08 | +29,120.78% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $8.48 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $13.07 | +1,162.43% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $62.00 | +262.90% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $6.03 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.86 | - | 2 | Jan 4, 2017 |
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $9.52
Upside: +57.56%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $2.43
Upside: +681.89%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $11.34
Upside: +164.55%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.05
Upside: +1,995.24%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $4.57
Upside: +425.16%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $21.01
Upside: +494.95%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $2.87
Upside: +527.18%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $2.23
Upside: +752.02%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.36
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: $600
Current: $8.71
Upside: +6,788.63%
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $175.40
Upside: -54.86%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $41.74
Upside: +271.35%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $7.56
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $6.20
Upside: +303.23%
Apr 30, 2021
Initiates: Outperform
Price Target: $61,200
Current: $9.28
Upside: +659,382.76%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $2.85
Upside: +63,057.89%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $36.54
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.91
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $2.91
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $4.61
Upside: +32,437.96%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $3.08
Upside: +29,120.78%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $8.48
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $13.07
Upside: +1,162.43%
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $62.00
Upside: +262.90%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $6.03
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.86
Upside: -